General
Preferred name
DACTINOMYCIN
Synonyms
Actinomycin D ()
Actinomycin IV ()
Actinomycin c1 ()
GNF-Pf-2290 ()
Cosmegen ()
Dilactone actinomycin d acid ()
NSC-3053 ()
NCI-C04682 ()
Dactinomycinum ()
Actinomycin x1 ()
Meractinomycin ()
Cosmegen Lyovac ()
Actinomycin-d ()
Oncostatin K ()
Actinomycin i1 ()
GNF-Pf-1977 ()
P&D ID
PD003038
CAS
50-76-0
Tags
natural product
drug
available
Approved by
FDA
First approval
1964
Drug Status
investigational
approved
Drug indication
Antineoplastic
Solid tumour/cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Cell lines
36
Organisms
2
Compound Sets
16
ChEMBL Approved Drugs
CHEMBL1554
ChEMBL Drugs
CHEMBL1554
Drug Repurposing Hub
DrugBank
DB00970
DrugBank Approved Drugs
DB00970
DrugCentral
774
DrugCentral Approved Drugs
774
DrugMAP
DM2YGNW
DrugMAP Approved Drugs
DM2YGNW
LINCS compound set
10489-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1554
NCATS Inxight Approved Drugs
1CC1JFE158
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
1254.63
Hydrogen Bond Acceptors
18
Hydrogen Bond Donors
5
Rotatable Bonds
8
Ring Count
7
Aromatic Ring Count
1
cLogP
0.73
TPSA
359.98
Fraction CSP3
0.61
Chiral centers
10.0
Largest ring
16.0
QED
0.12
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Antibiotics
RNA synthesis inhbitor
DNA-Directed RNA Polymerase Inhibitors
Transcription Inhibitors
"RNA synthesis inhbitor
Transcription Inhibitors"
RNA polymerase inhibitor
Pathway
Immunology/Inflammation
Member status
member
Indication
testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)
Target
POLR2A
Therapeutic Class
Anticancer Agents
Source data